Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children

Arıcan, Özer

doi:10.1111/j.1442-200x.2006.02229.x

Cited by 17 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies evaluating the effectiveness and clearance rates of IMQ for molluscum range between 33% and 77% for complete clearance, and comparable numbers for partial clearance rates when applied 3–5 times a week for 12 weeks (7,21,22). In another open‐label study, 13 healthy children having MC treated with IMQ, 33% showed complete clearance at the end of 4 weeks of treatment (23).…”

Section: Discussionmentioning

confidence: 99%

Comparative Study on the Efficacy, Safety, and Acceptability of Imiquimod 5% Cream versus Cryotherapy for Molluscum Contagiosum in Children

Al-Mutairi

Al-Doukhi

Al-Farag

et al. 2009

Pediatric Dermatology

View full text Add to dashboard Cite

To compare the efficacy, safety and acceptability of imiquimod (IMQ) 5% cream with cryotherapy for the treatment of molluscum contagiosum (MC) in children. Prospective, randomized, comparative, observer blinded study. A total of 74 children, with MC were divided randomly to receive treatment with either IMQ 5% cream (group A) 5 days a week or cryotherapy (group B) once a week until clinical cure or up to a maximum of 16 weeks. All the patients were followed up weekly during active treatment. The patients were followed-up for 6 months after clinical cure to look for recurrence. In the IMQ group (group A), the overall complete cure rate was 91.8% (34 of 37), 22 of the 37 patients cleared by the end of 6 weeks and 12 more patients cleared by the end of 12 weeks, while the remaining three patients (8.1%) did not clear even after 16 weeks. Whereas, in the cryotherapy group, all 37 patients achieved complete cure, 26 of 37 (70.27%) patients cleared after 3 weeks, and the remaining 11 (29.72%) cleared by the end of 6 weeks. No statistically significant difference was found between the overall complete cure rate in both groups at the end of maximum treatment period (16 weeks). Pain, bullae formation, pigmentary changes, and superficial scarring were more significantly common in the cryotherapy group compared with the IMQ group. Imiqimod 5% cream seems to be slow acting but an effective agent for the treatment of MC in children. IMQ appears to be practically painless and more cosmetically accepted treatment when compared with cryotherapy, and may be the preferred treatment of MC in children especially with numerous small lesions. Cryotherapy has the advantage of being rapidly effective, and is less expensive than IMQ and may be the preferred treatment for large solitary or few lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Study on the Efficacy, Safety, and Acceptability of Imiquimod 5% Cream versus Cryotherapy for Molluscum Contagiosum in Children

Al-Mutairi

Al-Doukhi

Al-Farag

et al. 2009

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…Destructive measures include curettage, cryotherapy, needle pricking, and topical vesicants such as cantharidin (2,3). Other destructive approaches include retinoids, silver nitrate, potassium hydroxide, salicylic acid, and phenols (4–14). Immunologic therapies include imiquimod, nitric oxide, and cimetidine, although the efficacy of these therapies remains controversial.…”

mentioning

confidence: 99%

Cantharidin for the Treatment of Molluscum Contagiosum: A Prospective, Double‐Blinded, Placebo‐Controlled Trial

Dosal

Stewart

Lin

et al. 2012

Pediatric Dermatology

View full text Add to dashboard Cite

Background/Objective To study the effects and safety of cantharidin in the treatment of molluscum contagiosum. Methods We conducted a prospective, double-blinded, placebo-controlled, randomized clinical trial to evaluate the safety and efficacy of topical cantharidin for treatment of pediatric molluscum contagiosum in an academic ambulatory care center. Twenty-nine children aged 5–10 with the diagnosis of molluscum contagiosum were enrolled to receive treatment with cantharidin or placebo. The main outcome measure was complete clearance of molluscum lesions. Results In contrast to previous retrospective observational studies, the performance of cantharidin treatment over 2 months was not substantially better than the performance of placebo. Limitations The scope of follow-up was limited to 5 visits over 2 months of treatment. In hindsight, we can hypothesize that a longer follow up period may have captured a greater effect of cantharidin. Conclusion We conclude that during a 2 month period, the magnitude of the cantharidin treatment effects in the target population are, at best, not large. This study provided objective unbiased estimates of the magnitude of cantharidin treatment effects and provided important prospective safety data. Our subjects experienced minimal side effects when treated with cantharidin.

show abstract

“…Apart from many ongoing trials, Food and Drug Administration approved TLR ligands, MPLA (TLR4 agonist), and imiquimod (TLR7 agonist) could be highlighted to address adjuvant or drug roles. MPLA has been used in various vaccine formulations, for instance, Fendrix (Hepatitis B vaccine, GSK), as an adjuvant and imiquimod is famously used to cure viral diseases as a drug . The majority of TLRs produce redundant responses (inflammatory vs antiviral); however, there are slight, but distinct, differences in outcomes .…”

Section: Tlr Ligands: Adjuvants Vs Drugsmentioning

confidence: 99%

Recent clinical trends in Toll‐like receptor targeting therapeutics

Anwar

Shah

Kim

et al. 2018

Medicinal Research Reviews

226

204

View full text Add to dashboard Cite

Toll‐like receptors (TLRs) are germline‐encoded receptors that are central to innate and adaptive immune responses. Owing to their vital role in inflammation, TLRs are rational targets in clinics; thus, many ligands and biologics have been reported to overcome the progression of various inflammatory and malignant conditions and support the immune system. For each TLR, at least one, and often many, drug formulations are being evaluated. Ligands reported as stand‐alone drugs may also be reported based on their use in combinatorial therapeutics as adjuvants. Despite their profound efficacy in TLR‐modulation in preclinical studies, multiple drugs have been terminated at different stages of clinical trials. Here, TLR modulating drugs that have been evaluated in clinical trials are discussed, along with their mode of action, suggestive failure reasons, and ways to improve the clinical outcomes. This review presents recent advances in TLR‐targeting drugs and provides directions for more successful immune system manipulation.

show abstract

Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children

Cited by 17 publications

References 16 publications

Comparative Study on the Efficacy, Safety, and Acceptability of Imiquimod 5% Cream versus Cryotherapy for Molluscum Contagiosum in Children

Comparative Study on the Efficacy, Safety, and Acceptability of Imiquimod 5% Cream versus Cryotherapy for Molluscum Contagiosum in Children

Cantharidin for the Treatment of Molluscum Contagiosum: A Prospective, Double‐Blinded, Placebo‐Controlled Trial

Recent clinical trends in Toll‐like receptor targeting therapeutics

Contact Info

Product

Resources

About